Indicator Analysis 2026

of the Certified Prostate Cancer Centres

Audit year 2025 / Indicator year 2024

DKG
GERMAN CANCER SOCIETY
Certification

Table of Content

Introduction 3
General Information 3
Status of the certification system: Prostate Cancer Centres 2025 5
Clinical sites taken into account 6
Tumour documentation systems in the centre's clinical sites 7
Basic data 8
Analysis of indicators 15
Indicator No. 1a: Number of primary cases of prostate cancer 15
Indicator No. 1b1: Distribution of primary cases with locally confined prostate carcinoma (PCa) and low risk 16
Indicator No. 1b2: Distribution of primary cases with locally confined prostate cancer and intermediate risk 17
Indicator No. 1b3: Distribution of primary cases with locally confined prostate cancer and high risk 18
Indicator No. 1c: Patients with new recurrence and/or distant metastasis 19
Indicator No. 2a: Presentation at the weekly pre-therapeutic tumour board – Urology 20
Indicator No. 2b: Presentation at the weekly pre-therapeutic tumour board – Radiotherapy 21
Indicator No. 3a: Presentation in the weekly tumour board - Primary cases post-operative 22
Indicator No. 3b: Presentation in the weekly tumour board - Primary cases with primary M1 pre-therapeutic 23
Indicator No. 3c: Presentation in the weekly tumour board - Recurrence/metastasis pre-therapeutic 24
Indicator No. 4: Active-Surveillance (AS) (GL QI) 25
Indicator No. 5: Percutaneous RT with hormone ablation therapy for locally confined PCa with high risk (GL QI) 26
Indicator No. 6: Psycho-oncological distress screening 27
Indicator No. 7: Social service counselling 28
Indicator No. 8: Patients enrolled in a study 29
Indicator No. 9: Surgical expertise 32
Indicator No. 10: Record of R1 resections for (y)pT2 c / pN0 or Nx M0 33
Indicator No. 11: Definitive radiotherapy 34
Indicator No. 12: Permanent seed implantation - D 90 > 130 Gy 35
Indicator No. 13: HDR brachytherapy 36
Indicator No. 14: Diagnostic report - Punch biopsy (GL QI) 37
Indicator No. 15: Diagnostic report - Lymph nodes (GL QI) 38
Indicator No. 16: Begin Salvage-radiotherapy for recurrent prostate cancer (GL QI) 39
Indicator No. 17: Postoperative complications after radical prostatectomy (RP) (GL QI) 40
Indicator No. 18: Adverse effects after radiotherapy (GL QI) 41
Indicator No. 19: Dental examination prior to bisphosphonate or denosumab therapy (GL QI) 42
Indicator No. 20: No hormone ablation therapy in the case of locally advanced prostate carcinoma with radical prostatectomy (GL QI) 43
Indicator No. 21: Focal therapy for locally advanced prostate cancer (GL QI) 44
Indicator No. 22: Rate of locally confined prostate carcinoma and low risk with RPE/RCE 45
Indicator No. 23: RPE/RCE in primary cases with locally confined prostate carcinoma and low risk 46
Imprint 47

General information



Quality indicators of the guidelines (LL QI):

In the table of contents and in the respective headings, the indicators which correspond to the quality indicators of the evidence-based guidelines are specifically identified. These quality indicators are based on the strong recommendations of the guidelines and were derived from the guidelines groups in the context of the German Guideline Programme in Oncology (GGPO). Further information: www.leitlinienprogramm-onkologie.de*
The quality indicators (QIs) refer to version 6.2 of the S3 GL on prostate cancer.



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with additional neo- and/or adjuvant hormone ablative therapy	11*	0 - 63	2,290	1,967
Denominator	Primary cases with prostate cancer T1-2 N0 M0 with high risk (PSA >20ng/ml or Gleason-Score ≥ 8 or cT category 2c) and percutaneous radiotherapy	14*	1 - 68	2,843	2,487
Rate	Target value ≥ 70%	82.8%	0% - 100%	80.5%**	79.1%

Basic data indicator:

The definition of the **numerator**, **denominator** and the **target value** are taken from the data sheet.
The **median** for numerator and denominator does not refer to an existing centre but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
Range specifies the value range for the numerator, denominator and ratio of all centres.
The column **Patients Total** displays the total of all patients treated according to the indicator and the corresponding quota.



Diagram:

The x-axis indicates the number of centres and the y-axis represents the values in percent or number (e.g. primary cases). The target value is depicted as a green horizontal line. The median, which is also depicted as a green horizontal line, divides the entire group into two equal halves.

*For further information on the methodological approach see „Development of guideline-based quality indicators" (https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Methodik/QIEP_OL_2021__Version_3_english_version.pdf)

General information



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	93.9%	94.4%	92.2%	93.2%	94.4%
Median	84.6%	82.7%	81.8%	80.0%	82.8%
25th percentile	65.2%	72.2%	71.4%	72.2%	73.4%
5th percentile	23.6%	39.7%	50.0%	46.7%	50.0%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Cohort development:

The cohort development in the years **2020**, **2021, 2022, 2023** and **2024** is presented in a box plot diagram. This chart provides the distribution overview of each cohort's indicator year and direct comparison to the previous year.



Boxplot:

A box plot consists of a **box with median**, **whiskers** and **outliers**. 50 percent of the centres are within the box. The median divides the entire available cohort into two halves with an equal number of centres. The whiskers and the box cover 90% of the centres. The extreme values are depicted here as dots.

Status of the certification system: Prostate Cancer Centres 2025

	31.12.2025	31.12.2024	31.12.2023	31.12.2022	31.12.2021	31.12.2020
Ongoing certification procedures	9	11	7	5	11	22
Certfied centres	185	172	161	156	146	131
Certified clinical sites	187	174	163	157	147	132

Clincial sites taken into account

	31.12.2025	31.12.2024	31.12.2023	31.12.2022	31.12.2021	31.12.2020
Sites included in the Annual Report	180	165	153	145	132	124
Correspond to	96.3%	94.8%	93.8%	92.3%	89.8%	93.9%
Primary cases total*	51,342	44,882	39,943	36,135	30,336	30,528
Primary cases per site (mean)*	285	272	261	249	230	246
Primary cases per site (median)*	226	211	196	180	172	171

*The figures are based on the clinical sites listed in the Annual Report.

This Annual Report looks at the Prostate Cancer Centres certified in the Certification System of the German Cancer Society. The basis for the diagrams in the Annual Report is the Data Sheet.

The Annual Report includes 180 of the 187 certified centre sites. Excluded are 6 sites that were certified for the first time in 2025 and 1 clinical site that was reinstated (data mapping of complete calendar year not mandatory for inital certifications).

A total of 51,982 primary cases of prostate cancer were treated at 187 clinical sites. A current overview of all certified sites is shown at www.oncomap.de.

The indicators published here refer to the indicator year 2024. They are the basis for the audits conducted in 2025.

Tumour documentation systems in the centre's clinical sites



Legende:	
Andere („others“)	System used in ≤ 3 clinical sites

The details on the tumour documentation system was taken from the Data Sheet (Basic Data Sheet). It is not possible to use more than one system. In many cases, support is provided by the cancer registries or there may be a direct link to the cancer registry via a specific tumor documentation system.

Basic data – Primary Cases Prostate Cancer

Total primary cases



	Total primary cases
Locally confined (T1/2, N0, M0), Low risk	8,437 (16.4%)
Locally confined (T1/2, N0, M0), Intermediate risk	21,575 (42.0%)
Locally confined (T1/2, N0, M0), High risk	12,922 (25.2%)
Locally advanced (T3/4, N0, M0)	2,105 (4.1%)
Advanced (N1, M0)	1,316 (2.6%)
Advanced (N0/1, M1)	3,614 (7.0%)
Not classified [1)]	1,373 (2.7%)
Total primary cases	51,342 (100%)

1) Not classified-: Nx, Mx, incidental findings after radical cystoprostatectomy

Basic data – Distribution non-interventional / interventional primary cases Prostate Cancer

Non-interventional / interventional primary cases



	Non interventional[1)]	Interventional	Total
Locally confined (T1/2, N0, M0), Low risk	3,998 (47.4%)	4,439 (52.6%)	8,437 (100%)
Locally confined (T1/2, N0, M0), Intermediate risk	1,439 (6.7%)	20,136 (93.3%)	21,575 (100%)
Locally confined (T1/2, N0, M0), High risk	313 (2.4%)	12,609 (97.6%)	12,922 (100%)
Locally advanced (T3/4, N0, M0)	36 (1.7%)	2,069 (98.3%)	2,105 (100%)
Advanced (N1, M0)	7 (0.5%)	1,309 (99.5%)	1,316 (100%)
Advanced (N0/1, M1)	25 (0.7%)	3,589 (99.3%)	3,614 (100%)
Not classified [2)]	147 (10.7%)	1,226 (89.3%)	1,373 (100%)
Total primary cases	5,965	45,377	51,342

1) Non-interventional: active surveillance or watchful waiting; histological evidence of prostate cancer mandatory PCa
2) Not classified : Nx, Mx, incidental findings after radical cystoprostatectomy

Basic data – Distribution of therapies Prostate Cancer

Non-interventional primary cases (locally confined) – Distribution of therapies



	Non-interventional[1)]		Total
	Active-Surveillance[1)]	Watchful Waiting[1)]	
Locally confined (T1/2, N0, M0), Low risk	3,550 (88.8%)	448 (11.2%)	3,998 (100%)
Locally confined (T1/2, N0, M0), Intermediate risk	1,066 (74.1%)	373 (25.9%)	1,439 (100%)
Locally confined (T1/2, N0, M0), High risk	150 (47.9%)	163 (52.1%)	313 (100%)
Total primary cases (locally confined), non-interventional treatment	4,766	984	5,750

1) Non-interventional: active surveillance or watchful waiting; histological evidence of prostate cancer mandatory

Basic data – Distribution of therapies Prostate Cancer

Primary cases - Distribution of therapies



	Non-interventional (Active surveillance, Watchful waiting)	Interventional - local treatment of the prostate[1)]	Interventional - exclusive systemic treatment	Interventional - other non-local treatment[2)]	Total
Locally confined (T1/2, N0, M0), Low risk	3,998 (47.4%)	4,395 (52.1%)	16 (0.2%)	28 (0.3%)	8,437 (100%)
Locally confinded (T1/2, N0, M0), Intermediate risk	1,439 (6.7%)	19,862 (92.1%)	150 (0.7%)	124 (0.6%)	21,575 (100%)
Locally confinded(T1/2, N0, M0), High risk	313 (2.4%)	12,018 (93.0%)	379 (2.9%)	212 (1.6%)	12,922 (100%)
Locally advanced (T3/4, N0, M0)	36 (1.7%)	1,915 (91.0%)	101 (4.8%)	53 (2.5%)	2,105 (100%)
Advanced (N1, M0)	7 (0.5%)	1,119 (85.0%)	129 (9.8%)	61 (4.6%)	1,316 (100%)
Advanced (N0/1, M1)	25 (0.7%)	716 (19.8%)	2,157 (59.7%)	716 (19.8%)	3,614 (100%)
Not classified [2)]	147 (10.7%)	1,177 (85.7%)	24 (1.7%)	25 (1.8%)	1,373 (100%)
Total primary cases	5,965	41,202	2,956	1,219	51,342

1) Interventional - local treatment of the prostate: e.g. radical prostatectomy (RPE), radical cystoprostatectomy (CPE), definitive percutaneous radiation, brachytherapy,
2) Interventional - other non-local treatment: e.g. palliative radiation of bone metastases, best supportive care.
3) Not classfied: Nx, Mx, incidental findings after radical cystoprostatectomy (CPE).

Basic data – Primary case distribution in the indicator years 2020-2024



Basic data – Distribution of interventional local therapies Prostate Cancer

Interventional primary cases treated - Distribution of therapies



	Interventional – local treatment of prostata							Total
	RPE [1]	CPE [2] due to PCa	Incidental finding after CPE [2]	Definitive percutaneous radiotherappy	LDR brachytherapy	HDR brachytherapy	Other local therapy[3]	
Locally confined (T1/2, N0, M0) Low risk	3,457 (78.7%)	17 (0.4%)	0 (0.0%)	652 (14.8%)	183 (4.2%)	10 (0.2%)	76 (1.7%)	4,395 (100%)
Locally confinded (T1/2, N0, M0) Intermediate risk	15,325 (77.2%)	31 (0.2%)	0 (0.0%)	4,057 (20.4%)	240 (1.2%)	60 (0.3%)	149 (0.8%)	19,862 (100%)
Locally confinded(T1/2, N0, M0) High risk	9,051 (75.3%)	35 (0.3%)	0 (0.0%)	2,843 (23.7%)	22 (0.2%)	50 (0.4%)	17 (0.1%)	12,018 (100%)
Locally advanced (T3/4, N0, M0)	1,180 (61.6%)	12 (0.6%)	0 (0.0%)	718 (37.5%)	1 (0.1%)	3 (0.2%)	1 (0.1%)	1,915 (100%)
Advanced (N1, M0)	570 (50.9%)	9 (0.8%)	0 (0.0%)	535 (47.8%)	0 (0.0%)	4 (0.4%)	1 (0.1%)	1,119 (100%)
Advanced (N0/1, M1)	265 (37.0%)	9 (1.3%)	0 (0.0%)	433 (60.5%)	0 (0.0%)	3 (0.4%)	6 (0.8%)	716 (100%)
Not classified [4]	74 (6.3%)	5 (0.4%)	1,021 (86.7%)	68 (5.8%)	6 (0.5%)	0 (0.0%)	3 (0.3%)	1,177 (100%)
Total primary cases	29,922	118	1,021	9,306	452	130	253	41,202

1) Radical Prostatectomy (RPE)

2) Radical cystoprostatectomy (CPE)

3) Other therapies: i.e. HIFU, …

4) Not classified : Nx, Mx, incidential finding after radical cystoprostatectomy (CPE)

Basic data – Distribution of therapies of prostate cancer patients with recurrence and metastasis

Newly diagnosed recurrence – distribution of therapies



Newly diagnosed remote metastasis – distribution of therapies



	Active-Surveillance	Watchful Waiting	RPE [1]	CPE [2] due to Pca	Incidential finding after CPE	Definitive percuaneous radiotherapy	LDR-Brachy-Therapy	HDR-Brachy-Therapy	other local Therapie [3]	Exclusive systemic therapy	Other therapy [4)]	**Total**
Pat. with newly diagnosed recurrence	0 (0.0%)	103 (1.9%)	109 (2.0%)	20 (0.4%)	0 (0.0%)	2,827 (52.7%)	3 (0.1%)	39 (0.7%)	73 (1.4%)	597 (11.1%)	1,589 (29.6%)	5,360 (100%)
Pat. with newly diagnosed remote metastasis	0 (0.0%)	15 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	799 (30.4%)	1,813 (69.0%)	2,627 (100%)

1) Radical Prostatectomy (RPE)

2) Radical Cystoprostatectomy (CPE)

3) Other therapies: i.e. HIFU, …

4) Not classified: Nx, Mx, incidential finding after radical cystoprostatectomy

1a. Number of primary cases of Prostate Cancer



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases	226	101 - 2837	51,342	44,882
	Target value ≥ 100				



	2020	2021	2022	2023	2024
Max	2660	2711	2512	2667	2837
95th percentile	502.6	522.4	581.2	568	656.7
75th percentile	244.3	277	278	301	305.5
Median	171.5	180	196	211	226
25th percentile	131.8	141	150	163	169.8
5th percentile	107	110.8	116.2	124	120.8
Min	86	89	102	100	101

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	180	100%	165	100%

Comments:
Over the last 4 years, the number of primary cases has risen across the entire spectrum. With a 9.1 % increase in the number of certified centres, the number of primary cases has risen by 14.4% compared with the previous year, whilst the median number of primary cases treated in the centres has risen by 7.1%. All centres have met the target value of at least 100 primary cases. Based on the latest incidence figures published by the cancer registry (ZfKD) of the Robert Koch Institute (RKI) (n = 79,613; 2023), the coverage of primary cases treated in all German centres stands at 58.1% (previous year: 54.6%).

1b1. Distribution of primary cases with locally confined Prostate Cancer and low risk



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases with locally confined PCa and low risk (PSA ≤ 10ng/ml and Gleason score 6 and cT category ≤ 2a)	36.5	3 - 339	8,437	7,484
	No target value				



	2020	2021	2022	2023	2024
Max	425	403	445	377	339
95th percentile	82.9	84	96.2	97	111.2
75th percentile	44	49	54	52	57
Median	29	29	31	36	36.5
25th percentile	18	19	22	25	24
5th percentile	10	9.2	12.6	12.2	12
Min	5	2	5	4	3

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	----	----	----	----

Comments:
In 42,934 patients (83.6% of all primary cases), the carcinoma was diagnosed at a locally confined stage (T1/2 N0 M0); of these, 8,437 – representing just under a fifth of the locally confined tumours – were classified as low-risk.

1b2. Distribution of primary cases with locally confined Prostate Cancer and intermediate risk



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases with locally confined Pca and intermediate risk (PSA > 10-20 ng/ml or Gleason score 7 or cT 2b)	88	18 – 1,760	21,575	18,618
	No target value				



	2020	2021	2022	2023	2024
Max	1557	1571	1373	1546	1760
95th percentile	194.7	218	246.2	258.4	245.5
75th percentile	94.3	107	112	125	127.5
Median	60	67	70	78	88
25th percentile	45.5	47	54	61	58.8
5th percentile	25.7	29	32	38.2	37
Min	9	15	15	20	18

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	----	----	----	----

Comments:
The steady increase over recent years in the number of primary cases of locally confined carcinoma (T1/2) and intermediate-risk disease has continued in the current indicator year: 42% of all primary cases had locally confined, intermediate-risk carcinoma at the time of initial diagnosis. On median, the centres treated 88 primary cases of locally confined prostate cancer with intermediate risk.

1b3. Distribution of primary cases with locally confined Prostate Cancer and high risk



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases with locally confined Pca and high risk (PSA > 20 ng/ml or Gleason score ≥ 8 or cT2c)	54.5	19 - 567	12,922	11,356
	No target value				



	2020	2021	2022	2023	2024
Max	627	654	515	570	567
95th percentile	155.7	152.8	155.6	161.6	193.7
75th percentile	65.3	67	76	76	78.3
Median	47.5	45	52	55	54.5
25th percentile	33	35	39	38	39
5th percentile	24.1	24	22.6	25.2	26
Min	14	16	13	20	19

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	----	----	----	----

Comments:
The proportion of primary cases involving locally confined, high-risk carcinoma is approximately at the same level as in previous years, accounting for 25.2% of all primary cases (previous year: 25.3%) and 30.1% of primary cases involving locally confined prostate cancer (previous year: 30.3%). The median number of primary cases treated at the centres in this tumour stage was 54.5 (previous year: 55).

1c. Patients with new recurrence and/or distant metastasis



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients with new recurrence and/or distant metastases	36	1 - 321	7,987	6,201
	No target value				



	2020	2021	2022	2023	2024
Max	157	137	215	142	321
95th percentile	101.7	92.9	90.1	100.3	113.3
75th percentile	48.8	50	50.3	48.5	61
Median	27.5	27	30	33	36
25th percentile	15	13.5	14.8	15	17
5th percentile	6	4.1	3	5.2	7
Min	1	1	1	1	1

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
179	99.4%	164	99.4%	----	----	----	----

Comments:
The number of patients with a new recurrence and/or distant metastases has increased by 28.8% (n = 1,786) and has thus risen significantly more sharply than the number of certified centres (+9.1%). With the median rising from 33 to 36, the number of cases has more than doubled at the centre with the highest number of patients with a new recurrence and/or distant metastases. One centre (not shown) did not treat any patients with a new event in the indicator year 2024.

2a. Presentation in the weekly pre-therapeutic tumour board – via Urology



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024 Median	Range	Patients total	2023 Patients total
Number	Patients of the denominator presented in the pre-therapeutic tumour board	156.5*	32 – 2,618	38,608	34,331
Denominator	Patients who present to urology or radiotherapy (e.g. via referral) and are diagnosed as primary cases according to CoR 1.2.1 (without primary M1, without incidental findings according to Radical Cysto-prostatectomy (CPE)).	158.5*	35 – 2,666	39,287	35,001
Rate	Target value ≥ 95%	99.3%	78.3% - 100%	98.3%**	98.1%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	98.3%	99.1%	98.9%	99.2%	99.3%
25th percentile	95.9%	97.1%	97.3%	97.4%	97.6%
5th percentile	81.0%	92.7%	94.7%	94.0%	95.2%
Min	62.0%	79.6%	28.1%	62.1%	78.3%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	173	96.1%	153	92.7%

Comments:
For years, the centres have been achieving a very high standard in presenting patients at pre-therapeutic tumour board (urology): the proportion of patients presented prior to treatment has risen further (98.3% vs. 98.1%). 96.1% of the centres met the target value. (previous year: 92.7%. Centres with referral rates of less than 95% cited, in particular, direct referral to surgery and tumour boards that had already taken place externally. Other reasons included documentation errors, as well as staffing shortages and oversights.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

DKG GERMAN CANCER SOCIETY Certification

2b. Presentation in the weekly pre-therapeutic tumour board – via Radiotherapy



Sollvorgabe = target value

160 clinical sites

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients of the denominator presented in the pre-therapeutic tumour board	28.5*	1 - 234	5,684	4,973
Denominator	Patients who present to urology or radiotherapy (e.g. via referral) and are diagnosed as primary cases according to CoR 1.2.1 (without primary M1, without incidental findings according to CPE).	28.5*	1 - 236	5,779	5,090
Rate	Target value ≥ 95%	100%	50% - 100%	98.4%**	97.7%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25th percentile	99.3%	100%	100%	99.4%	100%
5th percentile	80.1%	89.2%	90.3%	89.9%	90.9%
Min	30.4%	68.9%	33.3%	40.0%	50.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
160	88.9%	148	89.7%	150	93.8%	138	93.2%

Comments:
Given the very high baseline level, the proportion of patients referred primarily to radiotherapy who were seen prior to treatment has risen further (98.4% vs. 97.7%). 20 centres reported that no primary cases had been referred to them via the radiotherapy department. As in the previous year, 10 centres fell short of the target value. The centres stated that patients had already been discussed externally in an interdisciplinary tumour board.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

3a. Presentation in the weekly tumour board – Primary cases post-operative



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients of the denominator presented at the tumour board (post-operative: primary cases operated)	48*	15 – 1,217	13,279	11,007
Denominator	Primary cases > pT3a and/or R1 and/or pN+	49*	15 – 1,244	13,353	11,979
Rate	Target value = 100%	100%	73.9% - 100%	99.4%**	91.9%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25th percentile	100%	100%	100%	96.6%	100%
5th percentile	88.1%	95.5%	95.7%	66.1%	97.6%
Min	57.1%	75.0%	21.7%	39.1%	73.9%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	160	88.9%	112	67.9%

Comments:
Following a modification to the denominator (pT3 extension) and a temporary reduction in the presentation rate in the previous year (91.9%), 99.4% of the patients in the denominator were presented at the tumour board in the current indicator year, 2024. In 20 centres, not all patients in the denominator were presented as required. These centres stated that, in particular, patients who had died post-operatively were not presented. Other reasons included a lack of patient consent, oversights and transition processes following the indicator modification that had not yet been completed.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

3b. Presentation in the weekly tumour board – Primary cases primary M1 pre-therapeutic



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients of the denominator presented at the tumour board (pre-therapeutic: primary M1).	19*	1 - 60	3,639	3,055
Denominator	Primary cases with primary M1	19*	1 - 61	3,656	3,076
Rate	Target value = 100%	100%	90.5% - 100%	99.5%**	99.3%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25th percentile	100%	100%	100%	100%	100%
5th percentile	77.5%	94.1%	91.6%	97.1%	96.7%
Min	53.1%	80.0%	76.9%	81.8%	90.5%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	167	92.8%	153	92.7%

Comments:
As in previous years, more than 99% of primary cases with primary distant metastases were presented at the pre-therapeutic tumour board. In total, only 17 out of 3,656 primary cases in the denominator (= 0.46%) were not presented (9 centres with 1 single case, 4 centres with 2 primary cases each): These centres cited the patient's death prior to the tumour board, time pressure to treat, the initiation of palliative care or a palliative care unit (BSC), lack of consent, as well as a failure to present the case.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

3c. Presentation in the weekly tumour board: Patients with new recurrence and/or distant metastases pre-therapeutic



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients of the denominator presented at the tumour board (pre-therapeutic: recurrence/distant metastasis).	35*	1 - 321	7,864	6,042
Denominator	Patients with new recurrence and/or distant metastases (= indicator 1c)	36*	1 - 321	7,987	6,201
Rate	Target value = 100%	100%	42.9% - 100%	98.5%**	97.4%



	2019	2020	2021	2022	2023
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25th percentile	92.9%	96.3%	99.0%	100%	100%
5th percentile	60.0%	73.1%	77.8%	83.7%	90.4%
Min	20.0%	50.0%	0.0%	0.0%	42.9%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
179	99.4%	164	99.4%	138	77.1%	125	76.2%

Comments:
The referral rate for patients with a secondary event (new recurrence and/or metastasis) has risen to 98.5%. As in the previous year, just under a quarter of the centres failed to meet the target value of referring all patients in the denominator to the pre-therapeutic tumour board. In 15 centres, the target value was not met due to the failure to present a single case; in 25 centres, 57% of the patients in the denominator were not presented. The centres attributed this to oversights, external follow-up treatment and the death of patients.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

4. Active Surveillance (AS) (GL QI)



Begründungspflicht = mandatory justification

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases under AS	14*	0 - 95	3,550	2,685
Denominator	Primary cases with locally confined PCa and low risk (PSA ≤ 10ng/ml and Gleason-Score 6 and cT category ≤ 2a)	36.5*	3 - 339	8,437	7,484
Rate	Mandatory justification*** <0.01%	43.1%	0% - 95.2%	42.1%**	35.9%



	2020	2021	2022	2023	2024
Max	91.3%	95.2%	100%	100%	95.2%
95th percentile	71.0%	77.7%	78.0%	84.0%	83.4%
75th percentile	50.0%	50.0%	52.4%	54.4%	62.5%
Median	31.7%	34.4%	35.5%	36.8%	43.1%
25th percentile	15.7%	15.4%	14.3%	14.7%	22.0%
5th percentile	3.2%	0.0%	1.4%	0.1%	2.8%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the plausibility limits			
2024		2023		2024		2023	
180	100%	165	100%	173	96.1%	156	94.5%

Comments:
The proportion of patients undergoing active surveillance for primary cases with a locally confined (low-risk) disease continued to rise in the 2024 indicator year and now stands at 42.1% overall (previous year: 35.9%). In 7 centres, no primary cases were referred to the active surveillance programme; this was justified on the grounds of targeted referral to interventional therapy and at the request of the patient.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

5. Percutaneous radiotherapy with hormone ablation therapy for locally confined PCa with high risk (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with additional neo- and/or adjuvant hormone ablative therapy	11*	0 - 63	2,290	1,967
Denominator	Primary cases with prostate cancer T1-2 N0 M0 with high risk (PSA >20ng/ml or Gleason-Score ≥ 8 or cT category 2c) and percutaneous radiotherapy	14*	1 - 68	2,843	2,487
Rate	Target value ≥ 70%	82.8%	0% - 100%	80.5%**	79.1%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	93.9%	94.4%	92.2%	93.2%	94.4%
Median	84.6%	82.7%	81.8%	80.0%	82.8%
25th percentile	65.2%	72.2%	71.4%	72.2%	73.4%
5th percentile	23.6%	39.7%	50.0%	46.7%	50.0%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
178	98.9%	164	99.4%	150	84.3%	133	81.1%

Comments:
Following a downward trend on the indicator in previous years, the current indicator year shows a turnaround across the entire range. Both the median and the overall rate have risen within a wide range *[0–100%]*, whilst the proportion of centres meeting the target value has increased from 81% to 84%. The 28 centres with a rate of < 70% (31 in the previous year) attributed this primarily to patients refusing treatment, but also to the decision not to proceed with ADT due to cardiovascular risk or the patient's age. 2 centres cited discrepancies in the risk classifications (d'Amico vs. NCCN).

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

6. Psycho-oncological distress screening



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients of the denominator who were psycho-oncologically screened	161*	16 – 2,424	36,489	20,806
Denominator	Primary cases (= indicator 1a) and patients with new recurrence and/or distant metastases (= Indicator 1c)	272*	108 – 2,975	59,329	35,815
Rate	Target value ≥ 65%	65.3%	6% - 99.8%	61.5%**	58.1%



	2020	2021	2022	2023	2024
Max	----	----	----	99.8%	99.8%
95th percentile	----	----	----	88.5%	85.4%
75th percentile	----	----	----	69.1%	71.9%
Median	----	----	----	55.5%	65.3%
25th percentile	----	----	----	36.1%	45.4%
5th percentile	----	----	----	14.7%	21.8%
Min	----	----	----	0.6%	6.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	116	70.3%	92	51.1%	42	36.2%

Comments:
The proportion of patients undergoing psycho-oncological distress screening has risen to 61.5%. With a median of 65.3%, over half of the centres have met the target value. Most centres with an insufficient screening rate cited process deficiencies in patients in the outpatient setting receiving a non-interventional treatment regimen or radiotherapy (definitive percutaneous radiotherapy, brachytherapy) as the reason for a rate < 65%.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

7. Social service counselling



Begründungspflicht = mandatory justification

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients of the denominator who received counselling from the social service on an inpatient or outpatient basis	129.5*	0 – 2,541	31,668	25,689
Denominator	Primary cases (= indicator 1a) and patients with new recurrence and/or distant metastases (= indicator 1c)	272*	108 - 2975	59,329	51,083
Rate	Mandatory justification*** <50%	52.4%	0% - 95.1%	53.4%**	50.3%



	2020	2021	2022	2023	2024
Max	91.9%	92.6%	89.3%	94.4%	95.1%
95th percentile	75.7%	75.2%	77.0%	80.2%	77.7%
75th percentile	60.0%	64.0%	64.0%	64.2%	64.4%
Median	50.6%	53.8%	53.3%	53.7%	52.4%
25th percentile	36.7%	39.7%	39.8%	40.3%	40.6%
5th percentile	2.9%	2.5%	4.0%	3.5%	4.2%
Min	0.4%	0.4%	0.8%	0.3%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the plausibility limits			
2024		2023		2024		2023	
180	100%	165	100%	108	60%	103	62.4%

Comments:
The implementation of this indicator has remained unchanged for years. With a median of 52.4 % (previous year: 53.7%), the overall rate has risen to 53.4%. 60% of the centres fall within the plausibility corridor and have provided advice to more than 50% of primary cases and patients with a new event. Of the 72 centres required to make a mandatory justification, 22 were located in other European countries, where different legal regulations and responsibilities apply. The remaining centres stated that patients treated on an outpatient basis or without surgery did not receive counselling, or that patients had not taken up the offer of social service counselling.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

8. Patients enrolled in a study



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients who were included in a study with an ethical vote	79*	1 – 2,722	22,539	19,631
Denominator	Primary cases (= indicator 1a)	226*	101 – 2,837	51,342	44,882
Rate	Target value ≥ 5%	36.6%	0.5% - 171.5%	43.9%**	43.7%



	2020	2021	2022	2023	2024
Max	242.6%	153.5%	163.5%	209.4%	171.5%
95th percentile	90.1%	80.8%	75.6%	80.8%	76.2%
75th percentile	55.2%	52.4%	45.4%	50.5%	50.0%
Median	39.4%	38.4%	35.1%	35.0%	36.6%
25th percentile	24.3%	25.6%	23.2%	25.3%	22.8%
5th percentile	7.1%	10.5%	5.9%	7.8%	9.0%
Min	0.0%	0.9%	1.5%	0.7%	0.5%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	176	97.8%	162	98.2%

Comments:
The study inclusion rate remains virtually unchanged compared with the previous year. With more than 22,500 patients enrolled in studies, the overall rate has risen slightly to 43.9% (previous year: 43.7%). 4 centres (previous year: 3) enrolled fewer than 5% of their patients in a trial, based on the number of primary cases. These centres have taken countermeasures, either by restructuring the trial centre or by participating in a PCO (from 2025).

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

Individual Annual Report - Evaluation of site-specific key figures

What is the individual Annual Report?
In the individual annual report, the site-specific centre data is shown and compared to the other certified centres in the respective certification system of the German Cancer Society. In addition, the individual development of the centre is presented over the course of time.
The content and design of an individual Annual Report are based on the general Annual Reports. An example of an individual Annual Report is available at www.onkozert.de under General Information / Annual Reports.



Example centre (red bar) compared to the other certified centres

Who can receive the individual Annual Report?
The prerequisite for the preparation of the individual annual report is the publication of the general annual report (announcement on www.onkozert.de) as well as the depiction of the own centre in the general Annual Report (for example, centres with initial certification are not depicted in the audit year).In the case of multi-site centres, each site is shown in its own individual Annual Report. Only the general Annual Report is currently available for oncology centres.

	Indicator definition	Example centre 2018	2019	2020	2021	2022
Numerator	Patients referred by the denominator who received inpatient or outpatient counselling from social services	219	263	220	240	237
Denomintor	Primary cases (= indicator 1a) + patients with newly occurring recurrence (local, regional LN metastases) and/or distant metastases (= indicator 1b)	321	362	331	355	360
Rate	Mandatory justification*** <20%	8,22%	72,65%	66,47%	67,61%	65,83%

Individual development of the example centre over time

Extract from an individual Annual Report (indicator counselling social service)

How can I receive the individual Annual Report?

The individual Annual Report is made available for download as an electronic PowerPoint file on the Data-WhiteBox platform.

Access to an individual Annual Report differs depending on the certification system:

Colorectal, Prostate and Gynaecological Cancer Centres

- The individual Annual Report is made available for all Colorectal, Prostate and Gynaecological Cancer Centres by decision of the respective Certification Commission.
- The centres (centre management and centre coordination) are informed by email by OnkoZert about the availability of the respective individual Annual Report.
- The centres (centre management and centre coordination) are informed by email by OnkoZert about the availability of the respective individual Annual Report.

All other Organ Cancer Centres / Modules

- The centres (centre management and centre coordination) are informed by email by OnkoZert about the basic availability of the individual Annual Reports. From this point onwards, an individual Annual Report can optionally be ordered for a fee.
- The 'Individual Annual Report Order Form' is available at www.onkozert.de under General Information / Annual Reports. Orders can only be placed by persons who are registered with OnkoZert as contact persons (e.g. centre management, centre coordination, QMB, etc.)
- The costs for the respective individual Annual Reports are listed on the form.
- The preparation time is approx. 3 weeks after receipt of order.

9. Surgical expertise



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Radical prostatectomies (RPE) / total cystoprostatectomies (RCE) (see Basic Data)	115	43 – 2,659	31,190	28,058
	Target value ≥ 50				



	2020	2021	2022	2023	2024
Max	2,549	2,565	2,358	2,507	2,659
95th percentile	390.9	420	451.4	440.8	461.6
75th percentile	146.8	163	180	182	171.8
Median	84.5	97	96	108	115
25th percentile	59	61	68	75	73
5th percentile	38.6	42.2	47	50.2	51
Min	19	34	33	33	43

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	177	98.3%	159	96.4%

Comments:
The number of prostatectomies (+11.2%) has risen more sharply than the number of centres (+9.1%). Once again, there has been a marked increase in the median, from 108 to 115 (previous year: +12). 3 centres (previous year: 6) performed fewer than 50 RPE/RZE procedures, citing the lack of robotic-assisted surgery facilities as the reason; these centres were either considering the purchase of such a system or had plans to do so. In 2024, more than 80% of prostatectomies for carcinoma were performed in all German DKG-certified prostate cancer centres.

10. Record of R1 resections for (y)pT2 c / pN0 or Nx M0



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Surgeries of the denominator with R1	6*	0 - 84	1,701	1,596
Denominator	Operations on primary cases with (y)pT2 c/pN0 or Nx M0	67.5*	11 - 1455	18,185	16,406
Rate	Target value ≤ 15%	9.2%	0% - 36.4%	9.4%**	9.7%



	2020	2021	2022	2023	2024
Max	38.7%	31.4%	35.3%	27.3%	36.4%
95th percentile	22.1%	19.8%	21.0%	20.8%	22.2%
75th percentile	13.8%	14.3%	13.1%	14.3%	13.7%
Median	9.8%	9.1%	8.7%	10.3%	9.2%
25th percentile	5.7%	4.2%	5.5%	5.9%	4.8%
5th percentile	0.0%	0.1%	0.0%	1.3%	0.3%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	151	83.9%	138	83.6%

Comments:
Following an increase in the previous indicator year, the R1 resection rate has now fallen again and stands at a median of 9.2%. Overall, tumour-free status was not achieved in 9.4% of operations (in the denominator) (previous year: 9.7%). The proportion of centres with an R0 resection rate of < 85% stands at 16.1%, which is on a level with the previous year (29/180). 8 of the 29 centres with an R1 resection rate >15% were already flagged in the previous year. The auditors identified 5 instances of non-compliance.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

11. Definitive radiotherapy



Begründungspflicht = mandatory justification

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with definitive radiotherapy	45.5*	2 - 262	9,306	7,864
Denominator	Primary cases (= indicator 1a)	226*	101 - 2837	51,342	44,882
Rate	Mandatory justification*** <10% and >90%	19.2%	0.1% - 56.6%	18.1%**	17.5%



	2020	2021	2022	2023	2024
Max	61.3%	58.8%	56.8%	60.0%	56.6%
95th percentile	41.4%	44.2%	43.8%	45.6%	46.6%
75th percentile	29.0%	27.1%	28.7%	26.4%	28.0%
Median	18.6%	18.8%	17.3%	19.5%	19.2%
25th percentile	12.2%	10.6%	10.9%	11.0%	11.5%
5th percentile	3.5%	3.3%	4.0%	4.1%	3.9%
Min	1.0%	0.1%	0.1%	0.0%	0.1%

Clinical sites with evaluable data				Clinical sites meeting the plausibility limits			
2024		2023		2024		2023	
180	100%	165	100%	148	82.2%	131	79.4%

Comments:
The number of primary cases treated with definitive radiotherapy (+18.3%) has again risen disproportionately this year compared with the total number of primary cases (+14.4%). 18.1% of all primary cases (17.5% in the previous year) received radiotherapy. The number of centres in which <10% of primary cases received definitive radiotherapy has fallen from 34 to 32. These centres stated in particular that patients had decided against radiotherapy following open-ended counselling. Furthermore, it was stated that patients are specifically referred for surgery.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

12. Permanent seed implantation - D 90 > 130 Gy



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator in which D90 > 130 Gy was achieved	10.5*	1 - 141	443	354
Denominator	Primary cases with LDR mono-therapy	10.5*	1 - 146	452	359
Rate	Target value ≥ 90%	100%	94.2% - 100%	98%**	98.6%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25th percentile	99.3%	100%	100%	100%	100%
5th percentile	67.9%	66.7%	92.7%	93.3%	96.5%
Min	0.0%	66.7%	91.7%	93.3%	94.2%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
20	11.1%	21	12.7%	20	100%	21	100%

Comments:
Following strong growth over the last two years *(+33% and +45%)*, the number of primary cases treated with LDR monotherapy has once again risen significantly (+93, [+26 %]). A total of 452 patients were treated using permanent seed implantation; in 9 primary cases, a D 90 > 130 Gy was not achieved (= 2%). As in the previous year, all centres that treated at least 1 primary case (median 10.5) with LDR monotherapy met the target value of ≥ 90%.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

13. HDR brachytherapy



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with HDR brachytherapy	0*	0 - 25	130	137
Denominator	Primary cases (= indicator 1a)	226*	101 – 2,837	51,342	44,882
Rate	No target value	0%	0% - 15.5%	0.3%**	0.3%



	2020	2021	2022	2023	2024
Max	21.4%	15.6%	18.0%	16.5%	15.5%
95th percentile	3.8%	1.9%	3.0%	1.9%	1.0%
75th percentile	0.0%	0.0%	0.0%	0.0%	0.0%
Median	0.0%	0.0%	0.0%	0.0%	0.0%
25th percentile	0.0%	0.0%	0.0%	0.0%	0.0%
5th percentile	0.0%	0.0%	0.0%	0.0%	0.0%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	----	----	----	----

Comments:
Whilst there was a significant increase in the number of primary cases (+6,460, *[+14.4%]*), the number of HDR brachytherapy treatments fell from 137 to 130 (overall rate unchanged at 0.3%). In 154 centres (85.5%), no primary cases received HDR therapy. In 26 centres, at least one primary case was treated using HDR brachytherapy; the range was wide (*0–25*). More than half of all these treatments were carried out in the 4 centres with ≥12 HDR treatments.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

14. Diagnostic report – Punch biopsy (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with complete diagnostic report	189.5*	15 – 2,372	42,954	37,220
Denominator	Primary cases with punch biopsy	194*	15 – 2,825	44,862	39,135
Rate	Target value ≥ 90%	98.6%	65.5% - 100%	95.7%**	95.1%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	99.7%	99.6%	100%	100%	100%
Median	96.8%	97.1%	98.0%	98.5%	98.6%
25th percentile	86.0%	88.9%	90.6%	93.8%	94.7%
5th percentile	53.0%	80.6%	81.3%	89.4%	90.4%
Min	0.9%	27.8%	46.0%	67.7%	65.5%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	173	96.1%	156	94.5%

Comments:
In just under 96% of primary cases involving punch biopsy (previous year: 95.1%), the pathology reports were complete. In 7 centres (previous year: 9), the reports were incomplete in more than 10% of primary cases: these centres cited the incompleteness of external reports (and the completeness of reports produced by their own pathology department).

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator..

15. Diagnostic report – Lymph nodes (GL QI)



Sollvorgabe = target value

180 clinical sites

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with diagnostic reports stating: • pN category • number of affected lymph nodes in relation to resected lymph nodes	90*	7 – 2,154	25,510	23,543
Denominator	Primary cases with lymphadenectomy	90.5*	7 – 2,158	25,769	23,799
Rate	Target value ≥ 80%	100%	90% - 100%	99%**	98.9%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25th percentile	98.8%	98.9%	98.0%	98.7%	98.5%
5th percentile	93.1%	94.7%	91.1%	93.1%	93.6%
Min	60.9%	82.7%	80.4%	83.5%	90.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	180	100%	165	100%

Comments:
The completeness of the pathology reports for primary cases involving lymphadenectomy remains unchanged compared with the previous year: in 99% of primary cases, the pathology reports contain the required information on the N category and the ratio of affected to resected lymph nodes. All centres have met the target value.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

16. Begin salvage-radiotherapy (SRT) for recurrent Prostate Cancer (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients of the denominator with beginning SRT and PSA <0.5 ng/ml	8*	0 - 62	2,022	1,456
Denominator	Patients after RPE and PSA recurrence and SRT	10*	1 - 74	2,550	1,855
Rate	Target value ≥ 70%	82.6%	0% - 100%	79.3%**	78.5%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	81.8%	82.7%	81.5%	84.5%	82.6%
25th percentile	72.7%	71.0%	72.1%	72.6%	71.4%
5th percentile	37.5%	39.0%	50.0%	33.3%	48.9%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
177	98.3%	160	97%	143	80.8%	127	79.4%

Comments:
The indicator remains virtually unchanged compared with the previous year. Whilst the overall compliance rate rose slightly to 79.3%, the median fell to 82.6%. In 3 centres, no patient received salvage radiotherapy following PSA recurrence after prior RPE. 34 centres (33 in the previous year) failed to meet the target value and attributed this to delayed referral (PSA ≥ 0.5) by external clinicians. In individual cases, treatment only commenced once a PSA level of ≥ 0.5 ng/ml had been reached, following the ordering of a PSMA-PET scan.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

17. Postoperative complications after radical prostatectomy (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with compli-cations Clavien-Dindo grade III or IV within the first 6 months after radical prostatectomy (RPE)	2*	0 - 55	592	569
Denominator	Primary T1-2 N0 M0 and RPE (from the previous indicator year)	65*	16 – 1,416	17,106	15,521
Rate	Target value ≤ 15%	2.9%	0% - 20%	3.5%**	3.7%



	2020	2021	2022	2023	2024
Max	----	20.0%	29.4%	33.3%	20.0%
95th percentile	----	13.6%	10.6%	12.2%	12.1%
75th percentile	----	8.3%	6.1%	6.3%	5.6%
Median	----	4.0%	3.5%	3.5%	2.9%
25th percentile	----	0.5%	0.7%	0.0%	0.0%
5th percentile	----	0.0%	0.0%	0.0%	0.0%
Min	----	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
177	98.3%	161	97.6%	174	98.3%	159	98.8%

Comments:
The complication rate has fallen steadily following the modification of the indicator for the 2021 indicator year (excluding histologically confirmed T1/T2 cases) and stands at a median of 2.9% in the current indicator year (overall rate 3.5%). In 3 centres, more severe complications occurred in > 15% of primary cases (pT1/T2 N0 M0) and RPE from the previous year (28 patients in total). The most common complications in these patients were lymphoceles (20 cases), wound healing disorders/dehiscence (6 cases) and abdominal infections/peritonitis (2 cases) (some of which were reported more than once). In one patient each, post-operative haemorrhage and a distal ureteral injury requiring the insertion of a DJ stent occurred.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

18. Adverse effects after radiotherapy (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with complications CTCAE grade III or IV within the first 6 months after radiotherapy	0*	0 - 3	31	40
Denominator	Primary cases with definitive ratiotherapy (from the previous indicator year)	45.5*	2 - 199	9,755	8,245
Rate	Target value ≤ 3.5%	0%	0% - 4.8%	0.3%**	0.5%



	2020	2021	2022	2023	2024
Max	9.1%	4.9%	6.9%	16.7%	4.8%
95th percentile	2.7%	1.8%	2.3%	2.7%	2.3%
75th percentile	0.0%	0.0%	0.0%	0.0%	0.0%
Median	0.0%	0.0%	0.0%	0.0%	0.0%
25th percentile	0.0%	0.0%	0.0%	0.0%	0.0%
5th percentile	0.0%	0.0%	0.0%	0.0%	0.0%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
176	97.8%	160	97%	175	99.4%	158	98.8%

Comments:
In the 2024 indicator year, higher-grade adverse events (CTCAE Grade III/IV) were documented in 40 primary cases within the first 6 months following radiotherapy. At 0.3%, the incidence of adverse events is slightly lower than in the previous year (0.5%). The centre, which had a rate of 4.8%, had shown no particular issues with regard to this indicator in previous years and has reported a single case this year involving recurrent episodes of gross haematuria.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

19. Dental examination prior to commencement of bisphosphonate or denosumab therapy (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Patients of the denominator with recommendation of a dental examination before the start of bisphosphonate or denosumab therapy.	3*	0 - 42	697	706
Denominator	Patients with bisphosphonate or denosumab therapy	3*	1 - 42	740	737
Rate	Target value ≥ 90%	100%	0% - 100%	94.2%**	95.8%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25th percentile	60.0%	100%	100%	100%	100%
5th percentile	0.0%	50.0%	83.2%	50.0%	55.7%
Min	0.0%	0.0%	33.3%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
137	76.1%	135	81.8%	121	88.3%	122	90.4%

Comments:
The indicator covers a wide range: whilst in 43 centres (24%) no patients received bisphosphonate or denosumab therapy, in 137 centres up to 42 patients per centre received osteoprotective treatment. The proportion of patients recommended to undergo a dental examination prior to the start of treatment also varies considerably between centres: in 116 centres (= 85% of centres providing treatment), such an examination was recommended. The 16 centres (= 12%) with rates of <90% cited difficulties with documentation in particular. Other reasons included: pre-existing treatment, edentulism and non-attendance.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

20. No hormone ablation therapy in the case of locally advanced Prostate Cancer with radical prostatectomy (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with adjuvant hormone ablation therapy	0*	0 - 4	27	44
Denominator	Primary cases pT3-4 pN0 M0 and RPE	28.5*	4 - 832	8060	7282
Rate	Target value < 0.1%	0%	0% - 22.2%	0.3%**	0.6%



	2020	2021	2022	2023	2024
Max	30.0%	25.0%	28.6%	30.8%	22.2%
95th percentile	11.4%	9.4%	9.3%	3.9%	3.6%
75th percentile	0.0%	0.0%	0.0%	0.0%	0.0%
Median	0.0%	0.0%	0.0%	0.0%	0.0%
25th percentile	0.0%	0.0%	0.0%	0.0%	0.0%
5th percentile	0.0%	0.0%	0.0%	0.0%	0.0%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	164	91.1%	147	89.1%

Comments:
In 16 centres (previous year: 18), a total of 27 primary cases of locally advanced carcinoma following radical prostatectomy received hormone-ablation therapy. The centres mostly cited external initiation of hormone-ablation therapy or case-by-case decisions in cases of R1/R2 resections, high PSA levels or young age. The Certification Commission has followed the decision of the Quality Improvement (QI) Working Group of the guideline to cease collecting this quality indicator in future and has removed the indicator from the indicator set with effect from the 2026 audit year.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

21. Focal therapy for locally advanced Prostate Cancer (GL QI)



Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator who received focal therapy	0*	0 - 0	0	0
Denominator	Primary cases with locally advanced prostate cancer	7*	1 - 125	2,105	1,917
Rate	Target value < 0.1%	0%	0% - 0%	0%**	0%



	2020	2021	2022	2023	2024
Max	----	11.1%	0.0%	0.0%	0.0%
95th percentile	----	0.0%	0.0%	0.0%	0.0%
75th percentile	----	0.0%	0.0%	0.0%	0.0%
Median	----	0.0%	0.0%	0.0%	0.0%
25th percentile	----	0.0%	0.0%	0.0%	0.0%
5th percentile	----	0.0%	0.0%	0.0%	0.0%
Min	----	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
166	92.2%	153	92.7%	166	100%	153	100%

Comments:
As in the previous indicator year for which this indicator was recorded, not a single primary case of locally advanced carcinoma was treated focally; consequently, since records began, only 2 out of 7,830 primary cases have received focal therapy (= 0.026%). Now that the indicator has been fully implemented across the centres, the Commission has decided to cease collecting this indicator in future.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

22. Rate of locally confined Prostate Cancer and low risk with RPE/RCE (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases of the denominator with locally confined prostate carcinoma and low risk	11.5*	0 - 318	3,474	3,450
Denominator	Primary cases with RPE + RCE	113.5*	40 – 2,649	30,040	26,921
Rate	No target value	10.2%	0% - 34.8%	11.6%**	12.8%



	2020	2021	2022	2023	2024
Max	----	----	----	56.0%	34.8%
95th percentile	----	----	----	27.2%	23.9%
75th percentile	----	----	----	16.8%	15.4%
Median	----	----	----	11.3%	10.2%
25th percentile	----	----	----	7.9%	6.6%
5th percentile	----	----	----	3.0%	2.8%
Min	----	----	----	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	----	----	----	----

Comments:
11.6% of primary cases involving RPE or RCE had a locally confined prostate carcinoma with low risk (previous year: 12.8%). Both the median (10.2% vs. 11.3%) and the range (*[0–35%]* vs. *[0–56%]*) are below the previous year's levels.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

23. RPE/RCE in primary cases with locally confined Prostate Cancer and low risk (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients total	Patients total
Number	Primary cases with locally confined prostate carcinoma and low risk and RPE/RCE	11.5*	0 - 318	3,474	3,450
Denominator	Primary cases with locally confined prostate carcinoma and low risk	36.5*	3 - 339	8,437	7,484
Rate	No target value	34.9%	0% - 100%	41.2%**	46.1%



	2020	2021	2022	2023	2024
Max	----	----	----	99.6%	100%
95th percentile	----	----	----	83.9%	86.3%
75th percentile	----	----	----	57.9%	55.8%
Median	----	----	----	38.5%	34.9%
25th percentile	----	----	----	23.7%	17.5%
5th percentile	----	----	----	7.7%	7.4%
Min	----	----	----	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
180	100%	165	100%	----	----	----	----

Comments:
The proportion of primary cases involving low-risk carcinoma that underwent RPE/RZE has fallen year-on-year from 46.1% to 41.2%. Whilst the median is slightly lower (34.9% vs. 38.5%), the wide range of surgical rates (*0–100%*) remains striking.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

WISSEN AUS ERSTER HAND
(FIRST-HAND KNOWLEDGE)

DKG GERMAN CANCER SOCIETY Certification

Find out more on www.krebsgesellschaft.de

Authors
German Cancer Society (DKG)
Certification Committee Prostate Cancer Centres
Martin Burchardt, Spokesman Certification Committee
Dirk Böhmer, Spokesman Certification Committee
Aline Kaufmann, German Cancer Society (DKG)
Martin Utzig, German Cancer Society (DKG)
Ellen Griesshammer, German Cancer Society (DKG)
Fränze Wüst, German Cancer Society (DKG)
Daniela Miller, OnkoZert
Roxana Rentea, OnkoZert

Imprint
Publisher and responsible for content:
Deutsche Krebsgesellschaft (DKG)
Kuno-Fischer-Straße 8
14057 Berlin
Tel: +49 (030) 322 93 29 0
Vereinsregister Amtsgericht Charlottenburg.
Vereinsregister-Nr.: VR 27661 B
V.i.S.d.P.: Dr. Konstanze Blatt

in cooperation with:
OnkoZert. Neu-Ulm
www.onkozert.de

Version e-A1-en; 02.06.2026

ISBN: 978-3-912231-30-4